Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years
Rosanna Ruggiero, Nunzia Balzano, Raffaella Di Napoli, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12

Showing 12 citing articles:

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
Rosanna Ruggiero, Nunzia Balzano, Maria Maddalena Nicoletti, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 394-394
Open Access | Times Cited: 5
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
M.J. O’Hare, Amanda C. Guidon
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 509-525
Closed Access | Times Cited: 3
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Yanting Zhou, Hongyan Li
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 7
Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data
Andre Abrahao, Pedro Henrique de Magalhães Tenório, Mariana Rodrigues Pioli, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000544-e000544
Open Access | Times Cited: 2
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition
Vera Elisabeth Adreana Kleinveld, Julia Wanschitz, Wolfgang N. Löscher, et al.
Immunotherapy (2024) Vol. 16, Iss. 9, pp. 597-601
Closed Access | Times Cited: 1
Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma
Jeremy S. Abramson, Robert Stuver, Alex F. Herrera, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104499-104499
Open Access | Times Cited: 1
Chronic Inflammatory Demyelinating Polyneuropathy Induced by Immune Checkpoint Inhibitors: Case Reports
O. A. Tikhonova, Д. С. Дружинин, E. S. Druzhinina, et al.
Annals of Clinical and Experimental Neurology (2024) Vol. 18, Iss. 1, pp. 98-104
Open Access
Immune-Mediated Neuropathies: Top 10 Clinical Pearls
Elizabeth M. Monohan, Thomas H. Brannagan
Seminars in Neurology (2024)
Closed Access
Recent insights into haematology and peripheral nerve disease
Oliver Tomkins, Michael P. Lunn
Current Opinion in Neurology (2024) Vol. 37, Iss. 5, pp. 461-466
Closed Access
Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
Connor Frey, Mahyar Etminan
Antibodies (2024) Vol. 13, Iss. 3, pp. 56-56
Open Access
Synergistic effects of immune checkpoints and checkpoint inhibitors in inflammatory neuropathies: Implications and mechanisms
Aritrani Sarkar, Madhu Nagappa, Saikat Dey, et al.
Journal of the Peripheral Nervous System (2023) Vol. 29, Iss. 1, pp. 6-16
Closed Access | Times Cited: 1
Navigating Neurologic Adverse Events in Immune Checkpoint Inhibitor Therapy: Challenges and Strategies
Arzu Aldemir Atmaca
Eurasian Journal of Medical Advances (2023), pp. 88-104
Open Access
Page 1

Scroll to top